Trimex

Quick links to important sections

Trimex

Selected form

Method of action: Anorexigenic

Treatment option: Obesity

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trimex

Property Description
Active ingredient Phenylpropanolamine (PPA)
Form Oral dosage forms: Tablets, capsules, liquids, syrups
Pharmacological class Sympathomimetic agent
General purpose Decongestant and appetite suppressant (historical use)
Origin Synthetic non-catecholamine amine

1. The Core Identity: What is the Drug Phenylpropanolamine?

Trimex is a historical proprietary trade name for a medicine containing the active ingredient Phenylpropanolamine (PPA). This compound is a synthetic entity, classified chemically as a non-catecholamine sympathomimetic amine. It is a substituted amphetamine, also known by the synonym dl-norephedrine. The active substance is typically utilized as the hydrochloride salt and was available as a single-entity product and in various combination formulations.

2. Pharmacological Classification and General Purpose

Phenylpropanolamine is primarily classified as a sympathomimetic agent, functioning as an indirectly acting agent by increasing the release of certain natural neurotransmitters like norepinephrine in the body. This mechanism defines its broad utility, which was clinically recognized for two main general purposes: its effect as an oral decongestant and its use as an appetite suppressant. The sympathomimetic action is rooted in its ability to initiate vasoconstriction, which is the basic physiological mechanism that reduces swelling and tissue hyperemia in mucous membranes. Its status as an oral decongestant was formally recognized, confirming its ability to reduce swelling associated with nasal congestion.

3. Historical Forms and Route of Administration

The compound was widely manufactured for the oral route of administration, designed for systemic absorption upon ingestion. Phenylpropanolamine was historically available in various oral dosage forms, including tablets, capsules (including timed-release capsules), liquid solutions, and syrups. These forms facilitated its broad-reaching systemic effects, allowing the drug to address both nasal congestion and appetite regulation, positioning it historically as a drug for common ailments like the cold or general weight management concerns.

Regulatory References

  1. Phenylpropanolamine - MeSH - NCBI

What side effects are possible with Trimex?

The following information describes the official safety characteristics and adverse reactions associated with the active ingredient Phenylpropanolamine (PPA), the constituent of Trimex, based strictly on documentation from government regulatory authorities.

Serious Vascular and Cardiac Reactions

The safety profile is defined by a documented risk of serious adverse reactions, categorized primarily under Vascular Disorders and Cardiac Disorders. Official regulatory advisories have noted a connection between PPA use and an increased risk of hemorrhagic stroke, which may occur acutely, often within the first few days of starting treatment. Other serious events include hypertensive crisis (severe, sudden blood pressure elevation), ventricular arrhythmias, and myocardial infarction.

General Adverse Effects by System

Common adverse reactions, reflecting the drug's action as a sympathomimetic agent, are typically documented in the Nervous System and Psychiatric Disorders classes. These include insomnia, nervousness, restlessness, dizziness, and headache. Less serious but documented effects include tachycardia (increased heart rate), palpitations, nausea, and vomiting.

System-Organ Class Common Adverse Reactions Serious Adverse Reactions
Psychiatric/Nervous Insomnia, Nervousness, Dizziness, Headache Seizures, Psychosis
Cardiovascular/Vascular Palpitations, Tachycardia Hemorrhagic Stroke, Hypertensive Crisis, Arrhythmias
Genitourinary N/A Urinary retention (noted in men with prostatic hypertrophy)

Population-Specific Safety Considerations

Regulatory documentation identifies specific patient populations at a heightened safety risk. Safety constraints apply to individuals with uncontrolled hypertension, severe coronary artery disease, a history of stroke or cerebrovascular disease, or pheochromocytoma. Furthermore, the risk of urinary retention is specifically noted for men with existing prostatic hypertrophy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Trimex (Phenylpropanolamine) overdose describes severe manifestations resulting from excessive central nervous system (CNS) and cardiovascular stimulation. Documented signs in overdose situations include significant high blood pressure (Hypertension), irregular or fast heartbeat (arrhythmia), and psychiatric events such as hallucinations or seizures.

The most severe outcomes officially documented by regulators are hemorrhagic stroke (bleeding into the brain), hypertensive crisis (which may be accompanied by encephalopathy), and death. High overdose levels are associated with this elevated risk of severe vascular events. Accidental ingestion by a child may be fatal, and infants are noted as being especially sensitive to the effects of Phenylpropanolamine.

Regulators explicitly state that a person must seek emergency medical attention immediately for any suspected overdose or for the onset of severe manifestations, such as seizures or an irregular heartbeat. The official management approach is symptomatic and supportive, as no specific antidote is known. This includes careful monitoring of heart rate, blood pressure, and body temperature. Specific supportive measures described in regulatory guidance include the use of alpha-adrenergic blockers for severe hypertension and cooling techniques for marked hyperthermia.

Therapeutic Uses of Trimex

Trimex, which contains the active ingredient Phenylpropanolamine (PPA), was applied across domains where additional symptomatic support was needed, primarily focusing on respiratory discomfort and appetite management.

“The compound was generally considered relevant for situations involving disruptive symptom manifestations in both respiratory function and dietary management.”

Symptomatic Relief from Nasal and Sinus Congestion

Trimex was commonly used to address symptoms related to physical discomfort such as nasal obstruction and sinus fullness. It was applied in conditions presenting with acute or episodic manifestations, including the common cold, seasonal hay fever (allergic rhinitis), and chronic maxillary sinusitis. The primary therapeutic benefit supported the easing of symptoms that interfere with daily functioning, contributing to improved comfort during periods of heightened symptoms.


Managing Secretions and Appetite Control

The medication was applied in addressing symptom clusters characterized by excessive nasopharyngeal secretion, helping to ease the burden of a persistent runny nose (rhinorrhea). Furthermore, in a distinct therapeutic domain, its use was considered relevant for appetite regulation to assist with weight management for patients with moderate obesity on a supervised hypocaloric diet. This contributed to easing the overall symptom burden of persistent hunger, supporting the patient during difficult episodes.

Quick Fact: Support for Nasal Obstruction Symptoms

The medication was used for symptomatic relief in conditions involving mucosal swelling, with the primary benefit supporting the easing of physical discomfort related to nasal obstruction.

Eligibility and Restrictions for Use

The eligibility profile for Trimex (Phenylpropanolamine, PPA) is primarily defined by regulatory non-eligibility. The FDA recommends consumers not use any products containing PPA, classifying the ingredient as nonmonograph (Category II) for over-the-counter use due to an association with an increased risk of hemorrhagic stroke.


Official Contraindicated Populations

Official labeling strictly prohibits the use of PPA in populations with conditions sensitive to its sympathomimetic effects. PPA is formally contraindicated in patients with:

  • Severe Hypertension or pre-existing heart disease.
  • Hyperthyroidism, diabetes mellitus, or glaucoma.
  • Concomitant use with, or use within 14 days of taking, a Monoamine Oxidase Inhibitor (MAOI).

Special Population Restrictions

Population Group Regulatory Status
Pregnancy Use is generally contraindicated or historically assigned to Category C (restrictive use).
Lactation Discontinuation of nursing or the drug is advised due to potential risk to the infant.
Geriatric (Over 60) Considered more likely to experience side effects, requiring conditional use.
Organ Impairment Use requires caution in patients with liver disease or kidney insufficiency.

What should I know about interactions with other medicines?

Trimex Interactions with other medicines and products

Trimex, which contains the active ingredient Phenylpropanolamine (PPA), has formally documented interaction patterns established by regulatory authorities. These interactions mainly stem from PPA's classification as a sympathomimetic agent.

Formally Prohibited Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the high risk of severe hypertensive crisis. Regulatory rules mandate a two-week separation window after stopping an MAOI before PPA can be administered. The combination with other sympathomimetic drugs is also prohibited to avoid additive cardiovascular adverse effects.

Documented Pharmacodynamic Interactions

Interacting Agent Category Officially Documented Effect
Antihypertensive Agents (e.g., Beta Blockers) May decrease their therapeutic efficacy (antagonism).
Tricyclic Antidepressants (TCAs) Increases the risk of hypertension (additive effect).

Interactions with Ingestible Substances

Regulatory information advises that co-ingestion with alcohol should be avoided or limited due to an increased risk of cardiovascular and central nervous system side effects. Furthermore, an additive increase in blood pressure has been documented when PPA is co-administered with caffeine.

Exposure and Condition Constraints

The drug has been noted to reduce the clearance of substances like Theophylline. Conditions such as pre-existing Hypertension and Hyperthyroidism are also cited in regulatory documents as constraints, highlighting the increased clinical significance of these interactions in affected patient populations.

Mechanism of Action

Dual Action: Receptor Blockade and Smooth Muscle Relaxation

This medication acts through a combined dual mechanism: it functions as an antagonist on alpha-1 adrenergic receptors (alpha1) to block signals that cause blood vessels to constrict, while also directly signaling for smooth muscle relaxation in the local arteries. This two-pronged molecular action facilitates vasodilation by removing constrictive signals and simultaneously enhancing relaxation signals.


Modulating Intracellular Signaling for Enhanced Flow

The mechanism engages key intracellular pathways by increasing the levels of cellular messenger molecules, such as cyclic AMP (cAMP) and cyclic GMP (cGMP), through enzyme activation. The rise in these molecules acts as an intracellular second messenger, promoting the surrounding smooth muscle cells to decrease their tension. This molecular cascade leads to hyperperfusion, significantly increasing the rate and volume of arterial blood flow into the targeted tissue.


Resulting Physiological Effect: Tissue Turgor

The collective action of receptor blockade, direct muscle relaxation, and enhanced cellular signaling produces a reduction in vascular resistance. This increased blood inflow causes the expandable structures of the erectile tissue (corpus cavernosum) to fill and engorge under high pressure. This results in the physiological consequence of increased tissue turgor and rigidity.

Dosage and Administration Information

This section summarizes the formal instructions for the use of Trimex (Phenylpropanolamine) based on historical guidelines for the product.


Administration Scope

Feature Guideline
Route of administration Oral
Dosing schedule Nasal Congestion (Adults): 25 mg (IR) every 4 hours or 75 mg (ER) every 12 hours. Maximum daily dose is 150 mg. Weight Loss (Adults): 25 mg (IR) three times a day or 75 mg (ER) once a day. Maximum daily dose is 75 mg.
Timing in relation to meals (if applicable) For appetite control, the dose is taken one-half hour before meals.
Age-group administration rules Pediatric (2–12 years): Specific, lower IR doses are administered every 4 hours based on age. Renal Impairment: Requires administration of one-half of the normally recommended dosage.
Course Duration Constraints Use for weight loss is limited to 12 weeks. Use for symptomatic relief is limited to 7 days if symptoms persist.

Official Procedural Structure

The official use protocol is structured around highly specific numerical limits for dosage, frequency, and time duration, defining a controlled, short-term regimen for the medicine. The administration guidelines rely on the oral route across immediate-release and extended-release forms, which dictates the required interval between doses. Adherence to the maximum daily dose is mandatory, and provisions for age and impaired renal function define necessary adjustments to the standard labeled dose, ensuring controlled use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Phase Trials (Phase I-II)

Initial clinical research explored the question of whether it met predetermined endpoints related to function and safety for its intended use. These trials primarily investigated whether participants reported a reduction in pain scores over the study period.

  • Dose-Finding: Trials typically investigated starting with a low dose to determine the dosage used in later studies. The initial findings indicated a wide range of participant tolerance, which led researchers to determine the need for further investigation in later phases.
  • Safety Profile: Early phase studies reviewed the safety profile and research has explored combination use with common non-steroidal anti-inflammatory drugs (NSAIDs). The initial adverse event reporting focused on gastrointestinal discomfort and transient headache.

Phase III Randomized Controlled Trials (RCTs)

Large-scale Phase III trials were conducted globally. These studies primarily compared the compound against a placebo or an active comparator.

  • Primary Efficacy Endpoint: The main outcome measured was joint function using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. Researchers examined whether it was associated with changes in joint mobility scores and stiffness scores compared to placebo.
  • Pain Management: Secondary analysis evaluated the time-to-first-reported change in symptoms and reviewed changes in patient-reported pain scores over a 12-week period. The compound was studied to analyze data related to inflammation and swelling markers. Reports from the RCTs indicate that findings were complex, with some showing a statistically significant difference from placebo, while others did not.

Long-Term Safety and Combination Use

Extended duration studies (up to one year) monitored for potential long-term side effects.

  • Safety Monitoring: Extended duration studies did not record new serious adverse events not observed in the shorter studies.
  • Comparative Trials: This formulation was compared to previous versions in trials to assess tolerability differences. Studies reviewed data on bone density when the combination was administered alongside a standard calcium/Vitamin D regimen in a small subset of the total patient group.

Key Studies & References

  1. The Effect on Knee Joint Loads of Analgesic Use Compared With Exercise in Patients With Knee Osteoarthritis - A Single Blind RCT (NCT01638962)
  2. ICH Harmonised Guideline: General Considerations for Clinical Trials (E8)

Frequently Asked Questions (FAQ)

Common questions about Trimex (FAQ)


Q: How long does it usually take to feel the effects of Trimex?

Official information indicates that for immediate-release forms, peak concentrations of the active ingredient are generally measured in the blood about 1 to 2 hours after administration. For extended-release forms, this process may take longer, with peak blood concentrations often occurring within 3 to 4.5 hours.


Q: Are there any specific foods or drinks to avoid while using Trimex?

Regulatory documentation specifically advises that the consumption of alcohol should be avoided or significantly limited while using this medicine. Official product information notes a potential for an additive increase in blood pressure when used alongside substances containing caffeine.


Q: Can older adults generally use Trimex without special concerns?

Official documentation notes that individuals over 60 years of age are considered more likely to experience side effects of the drug. For this reason, official guidance suggests that conditional use, potentially involving adjusted amounts, may be relevant for consideration in this population.


Q: How long is Trimex typically used for (short-term vs. long-term)?

Official guidance specified limits on the duration of use based on the treated condition. For its historical use as an appetite suppressant for weight loss, use was typically limited to 12 weeks. For the relief of short-term symptoms like nasal congestion, use was generally limited to 7 days.


Q: Can I use Trimex if I am traveling to a different country?

The regulatory status of the active ingredient varies widely across the globe. While the FDA formally recommends against its use in the United States, it may be classified as a prescription-only medicine (or other controlled status) in other international jurisdictions. Information regarding the use of the medicine must align with the laws and regulations of the specific jurisdiction.


Q: Is it safe to use Trimex if I'm taking vitamins or minerals?

Specific interactions with most common vitamins and minerals are generally not detailed in the core regulatory documentation. However, because this drug is a sympathomimetic agent (which affects the nervous system), the need for caution is suggested when combining it with any substance that could influence heart rate or central nervous system activity.


Q: Is Trimex the same type of medicine as [similar common drug name]?

The active ingredient in Trimex is officially classified as a sympathomimetic agent, meaning it works by affecting the nervous system. This pharmacological classification places it in the same general class as some other decongestants, but its specific chemical structure and formal safety profile are different from those other compounds.


Q: Do studies show that Trimex is effective for the conditions it treats?

While the compound was historically approved and used for its intended purposes, the FDA’s action to request the withdrawal of products focused primarily on documented safety concerns (increased risk of hemorrhagic stroke) rather than on clinical evidence themes related to its intended use.


Q: Is it true that Trimex can cause a metallic taste in the mouth?

A metallic taste is not commonly listed as a primary side effect of the main active ingredient in official adverse event reports. However, the substance was often combined with other medications (such as certain antihistamines) whose own documented side effects can sometimes include a change in the senses of smell or taste.


Q: Can people with kidney issues use Trimex safely?

Regulatory documents state that use in individuals with impaired kidney function requires special consideration. For this patient group, official guidelines specify that an adjustment, such as one-half of the normally recommended dosage, may be necessary.


Q: Is Trimex available as a generic medicine?

Historically, products containing the active ingredient were manufactured and sold by various companies under both brand names (like Trimex) and generic formulations. Currently, the FDA has formally withdrawn approval for all such applications for human use in the United States.


Q: Does the time of day I use Trimex matter?

For its historical use as an appetite suppressant, official documents noted that the dose was intended to be taken one-half hour before meals. For extended-release forms used for weight loss, the dose was typically noted to be taken once a day in the morning.


Q: Why do official documents say Trimex is a 'Schedule X' drug?

The active ingredient is formally categorized as a List I chemical under the U.S. Controlled Substances Act (CSA) and, in some U.S. states, has been designated as a Schedule III drug. This classification is an administrative measure that imposes controls on its production and distribution.


Q: Does the way Trimex is used depend on the condition being treated?

Official regulatory documents detailed different administration plans based on the condition being addressed. The total amount permitted in a day, as well as the frequency of administration, differed depending on whether the drug was used for nasal congestion or weight loss.


Q: Can I buy Trimex without a prescription in some places?

Historically, the product was available in the U.S. and some other countries as an over-the-counter (OTC) product. However, due to safety findings, its current legal status has changed in many international jurisdictions, which now classify it as prescription-only.

How should Trimex be stored and disposed of?

How to Store and Dispose of Trimex?

The storage and disposal instructions for Trimex (Phenylpropanolamine) are based on mandatory requirements documented in regulatory labeling to maintain product stability and ensure public safety.

Official Storage Requirements

The product must be stored in a cool and dry place, within the defined temperature range of 10 C to 25 C, and protected from light. To ensure stability, containers must be kept tightly closed and stored away from incompatible substances. For safety, the medicine must be stored in a secure area and kept out of the sight and reach of children.

Regulatory Disposal Mandates

Disposal of any unused or expired product must be carried out in accordance with all local regulations. It is strictly required that the medicine and its container do not enter surface water or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trimex found in:

A-Z Index: